A randomized open labelled clinical study on the efficacy of Shadushana Guggulu with Udvartana in Sthoulya with specical refernce to primary obesity and its comparision with the efficacy of Navaka Guggulu with Udvartana

Obesity is defined as an abnormal growth of the adipose tissue due to an enlargement of fat cell size (hypertrophic obesity) or an increase in fat cell number (hyperplasic obesity) or a combination of both.Primary obesity (Type 1 Obesity) is not caused by any disease and its prevalence is amongst people who are accustomed to sedentary lifestyle, alcohol addiction and due to change in food habits and biological clock disturbance. According to WHO, 1.9 billion adults above age of 18 years were over-weight, out of which 650 million were obese,in 2022.The prevalence of obesity has been increased multi fold within the last 20 years and continue to rise. In India, more than 135 million individuals are affected with obesity with more prevalence of abdominal obesity. Mortality rate due to obesity and its related complications are increasing day by day. Obesity is a chronic condition requiring long-term management due to its associated health risks and high relapse rates. Despite lifestyle modifications like diet, exercise, and behavioral therapy being essential for all individuals with BMI more or equal to 25 sustained weight loss remains challenging. Pharmacotherapy such as Tetrahydrolipstatin may be considered in higher BMI or comorbid cases, but treatment options are limited and often have side effects. Hence, there is a growing need for effective, safe, and sustainable interventions in obesity management. The trial drug under consideration, Shadushana Guggulu ,is explained in the Yogaratnakara Medoroga Adhyaya. Navaka gugguluconsisting of Maricha, Pippali, Shunti, Haritaki, Vibhitaki, Amalaki, Chitraka,andMustamentioned in Bhaishajyaratnavali , Medoroga chikitsa upakrama  being a proven drug for Medohara is taken as control drug.